The Physician and Sportsmedicine
Menubar Home Journal Personal Health Resource Center CME Advertiser Services About Us

Hypertrophic Cardiomyopathy

Practical Steps for Preventing Sudden Death

Barry J. Maron, MD

Exercise and Sports Cardiology Series
Editor: Paul D. Thompson, MD


In Brief: Hypertrophic cardiomyopathy (HCM) is a rare cause of death among the many participants in sports and recreational athletics, but it attracts widespread attention because the deaths occur in young, apparently healthy people. Differentiating HCM from conditioning hypertrophy (athlete's heart) remains a challenge. Routine detection of HCM patients is most commonly done with family history, physical examination, electrocardiography, and echocardiograhy. Keys to the differential diagnosis include evidence of heterogenous left ventricle hypertrophy, left atrial enlargement, unusual ECG patterns, and family history or gene mutations. Molecular detection methods for known defective genes in HCM have not yet become routine clinical tools. Athletes with unequivocal HCM should not participate in competitive sports, except for perhaps some low-intensity ones.

Sudden death from cardiovascular disease during competitive sports in young athletes appears to be rare, affecting about 1 in 200,000 high school athletes per academic year (1). Higher estimates of the risk for sudden death have been calculated in apparently healthy male athletes, joggers, and marathon racers (eg, 1 in 15,000 to 1 in 50,000) (2-4).

While such estimates might suggest to some that public concern about these tragic events is disproportionate to their impact on the population, the emotional and social impact of athletic-field catastrophes remains high. To the public and physicians alike, competitive athletes symbolize the healthiest segment of our society, and the unexpected collapse of these young people always has a profound psychological impact (5). As such, sudden death continues to represent an important medical issue.

Profile of Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM, figure 1: not shown) is the single most common cardiovascular cause of sudden death in young athletes (table 1) (6-9). It usually occurs in the nonobstructive form and accounts for about 35% of these deaths (6). The disorder is a primary and familial cardiac malformation with a heterogeneous expression and a diverse clinical course for which disease-causing mutations in 10 genes encoding sarcomeric and regulatory proteins have been reported (10-19). HCM is a relatively uncommon cardiac malformation in the general population, recognizable clinically in about 1 in 500 (0.2%) (20).

TABLE 1. Causes of Sudden Cardiac Death in Young, Competitive Athletes in the United States

Cause Percent

Hypertrophic cardiomyopathy (HCM) 36
Cornary anomalies 19
Increased cardiac mass (not diagnostic of HCM) 10
Ruptured aorta 5
Tunneled left anterior descending coronary artery 5
Aortic stenosis 4
Arrhythmogenic right ventricular dysplasia 3
Dilated cardiomyopathy 3
Myocarditis 3
Coronary artery disease 2
Mitral valve prolapse 2
Other 6
Noncardiac 2

Clinical profile. HCM-related sudden death in nonathletes (as well as athletes) has been most common in young, asymptomatic individuals, occurring frequently during moderate or severe exertion, similar to its demographic profile in athletes (10,11,21). Despite intense investigation, however, reliable identification of the individual HCM patient at high risk remains a major challenge. This stems, in part, from the fact that most data on risk stratification were compiled at referral institutions and derived from selected patient populations known to be at increased risk (22).

Nevertheless, variables that currently appear to identify young HCM patients at greatly increased risk include prior aborted cardiac arrest or sustained ventricular tachycardia, family history of sudden or other premature HCM-related death, or identification of a high-risk genotype, multiple-repetitive or prolonged nonsustained ventricular tachycardia on ambulatory (Holter) electrocardiogram (ECG) recordings, recurrent or exertional syncope, and massive (>=30-mm wall thickness) left ventricular hypertrophy (LVH) (14,15). Magnitude of the left ventricular (LV) outflow tract pressure gradient has not been independently associated with an increased risk for sudden death.

Demographics of sudden death. Studies (6-9,23-25) of young, competitive US athletes who died suddenly show that they participated in a variety of sports, most often basketball and football (about 70%), a fact that probably reflects the popularity and intensity of these sports. About 90% of athletic-field deaths occurred in males; the relative rarity in females probably reflects lower participation levels, and sometimes less-intense levels of training. About 60% of athletes were high school age at the time of death.

Timing of collapse. Most athletes who experience sudden death (with HCM or other diseases) had been symptom free and not suspected of having cardiovascular disease. Sudden collapse was usually associated with exercise, predominantly in the late afternoon or early evening (6). Nonathletes with HCM, in contrast, had a prominent early- to mid-morning peak, similar to that of patients with coronary artery disease (26). In HCM, intense athletic participation may trigger potentially lethal tachyarrhythmias.

Racial differences. Although most reported sudden deaths in competitive athletes have been in white males, more than 40% have occurred in African-American athletes (6,25,27). This contrasts sharply with the very infrequent identification of black patients with HCM in hospital-based populations (25) and highlights the disparity in access to subspecialty healthcare for diagnosis. Consequently, young African-American athletes with HCM are less likely to be disqualified from competition (28).

Morphology and Heterogeneity

LVH has traditionally been regarded as the gross anatomic marker and likely determinant of many of the clinical features and course in most patients with HCM (see figure 1: not shown) (10-13,15). Since the LV cavity is usually small or normal in size, increased LV mass is due almost entirely to an increase in wall thickness.

Morphology. The clinical diagnosis of HCM has been based on the definition (by two-dimensional echocardiography) of the disease's most characteristic morphologic feature: LV wall thickening associated with a nondilated cavity and—in the absence of another cardiac or systemic disease—capable of producing the magnitude of hypertrophy present (eg, systemic hypertension or aortic stenosis) (10-13). Because the nonobstructive form of HCM is predominant (13-15), the well-described clinical features of dynamic obstruction to LV outflow—such as a loud systolic ejection murmur, systolic anterior motion of the mitral valve, or partial premature closure of the aortic valve—are not required for diagnosis.

HCM heterogeneity. Based on both ECG and necropsy analyses in many patients, the HCM disease spectrum has been characterized by vast structural diversity of patterns and extent of LVH (13,29). While the anterior ventricular septum is usually the predominant region of hypertrophy, virtually all possible patterns of LVH occur in HCM, and no single phenotypic expression can be considered "classic" or typical. For example, although many patients show diffusely distributed hypertrophy, about 30% demonstrate localized wall thickening confined to only one LV segment.

Absolute thickness of the LV wall varies greatly, though the average reported value in HCM is usually 21 to 22 mm (13). Wall thickness is profoundly increased in many patients, up to 60 mm (30). In contrast, the HCM phenotype is not always expressed as a greatly thickened left ventricle, and some patients show only a mild increase of up to 15 mm, including a few genetically affected individuals with normal thicknesses (¾12 mm) (18,31). Patterns of wall thickening in HCM are often strikingly heterogeneous, involving noncontiguous LV segments. Transitions between thickened areas and regions of normal thickness are often sharp and abrupt, not infrequently creating right-angled contours. Even first-degree relatives with the disease usually show considerable dissimilarities in the pattern of LV wall thickening (32).

Detection During Preparticipation Screening

While HCM may be suspected during preparticipation sports evaluations by the prior occurrence of exertional syncope, family history of the disease or of premature cardiac death, or by a loud heart murmur, such clinical features are relatively uncommon among all affected individuals. Of note, most HCM patients have the nonobstructive disease form that characteristically has no murmur or only a soft heart murmur (15). Consequently, the history and physical exam alone cannot be expected to reliably and consistently identify this disease (33). One study (3) showed that potentially lethal cardiovascular abnormalities, including HCM, were suspected by the standard preparticipation exam in only 3% of 115 high school and collegiate athletes who ultimately died suddenly of such diseases.

Even when noninvasive testing (eg, echocardiography) is employed, false-negatives may occur in athletes who have HCM but an incomplete phenotypic expression, usually during adolescence (34,35). Indeed, in individuals with HCM younger than age 13 to 15, LVH is often absent or mild, and therefore ECG findings (and phenotypic expression) may not be diagnostic during preparticipation screening (see "Lessons From an HCM Case Report," page 21).

Differentiating Between HCM and Athlete's Heart

In some young athletes, hypertrophy involving the anterior ventricular septum (wall thicknesses of 13 to 15 mm) is consistent with a relatively mild morphologic expression of HCM, and it may be difficult to distinguish from physiologic LVH that arises from athletic training (ie, athlete's heart) (36). While this distinction cannot always be resolved with certainty, careful analysis of echocardiographic and clinical features permits diagnostic differentiation in most instances (figure 2: not shown) (36).

Wall thickness. Although the region of predominant LV wall thickening always involves the anterior septum, in highly trained athletes the thicknesses of other wall segments are similar (37). Absolute increases in LV wall thickness within the diagnostic "gray zone" from athletic training have been identified most commonly in sports such as rowing and cycling, but not as a consequence of isometric training (38). While the anterior portion of septum is also usually the region of maximal wall thickening, in HCM areas other than the anterior septum (eg, posterior septum and anterolateral free wall or apex) may show the most marked thickening (13,29).

Cavity dimension. An enlarged LV end-diastolic cavity dimension (>55 mm) is present in more than one third of highly trained, elite male athletes (39). Conversely, the diastolic cavity dimension is small (<45 mm) in most HCM patients and is greater than 55 mm only in those who proceed to end-stage disease with progressive heart failure and systolic dysfunction (40). Therefore, in some instances, it is possible to distinguish athlete's heart from HCM solely on the basis of this measure (36).

Doppler transmitral waveform. Abnormalities of LV diastolic filling have been identified noninvasively with pulsed Doppler echocardiography (41). Most patients with HCM, including those with relatively mild hypertrophy that could be confused with athlete's heart, show abnormal Doppler diastolic indexes of LV filling and relaxation independent of whether symptoms or outflow obstruction are present (41,42). In comparison, trained athletes have invariably demonstrated normal LV filling patterns (43-47). Consequently, in an athlete suspected of HCM, a distinctly abnormal Doppler transmitral flow-velocity pattern strongly supports this diagnosis, while a normal Doppler study is compatible with either HCM or athlete's heart (42).

Gender. Sex differences in cardiac dimensions and LV mass have been identified in trained athletes (48-50). For example, female athletes rarely show LV wall thicknesses greater than 12 mm (51). Therefore, female athletes with wall thicknesses within the diagnostic gray zone are most likely to have HCM.

Deconditioning. Increased LV cavity size or wall thickness can be shown to be a physiologic consequence of athletic training by serial echocardiographic exams. After a short period of athletic deconditioning, decreases in cardiac dimensions and mass are evident (52-54). Elite athletes with LVH may show a reduction in wall thickness of about 2 to 5 mm with 3 months of deconditioning (54). An unequivocal decrease in LV wall thickness with deconditioning is inconsistent with pathologic hypertrophy and HCM.

ECG findings. Because of the wide variety of ECG alterations in athletes without cardiovascular disease (55) and patients with HCM (53), the 12-lead ECG is not particularly useful in distinguishing between these two entities.

Familial aggregation and genetics. The most definitive evidence for the presence of HCM in an athlete with increased wall thickness comes from the demonstration of the disease in a relative (16-18,31,56-58). Therefore, in athletes in whom the distinction between HCM and athlete's heart cannot be achieved definitively by other methods, echocardiographic screening of family members may resolve the diagnosis (57). Absence of HCM in a family, however, does not exclude the diagnosis since HCM may be sporadic, presumably due to de novo mutation.

Identification of the genetic alterations causing HCM raises the possibility of DNA diagnosis in athletes suspected of having the disorder. At present, mutations responsible for HCM have been identified in 10 genes, each of which encode proteins of the sarcomere: beta-myosin heavy chain, alpha-myosin heavy chain, cardiac troponin T, troponin-1, myosin-binding protein C, alpha-tropomyosin, essential and regulatory myosin light chains, titin, and actin (16-19,31,56-61). This substantial genetic heterogeneity and the requisite expensive, time-intensive methods currently make using molecular biologic techniques difficult for routine clinical resolution of athlete's heart versus HCM.

Eligibility Considerations

When a cardiovascular abnormality such as HCM is identified in a competitive athlete, physicians must consider: (1) the magnitude of risk for sudden cardiac death associated with continued participation, and (2) the criteria used for determining whether individual athletes should be withdrawn from competition.

The 26th Bethesda Conference. This conference (28) offers recommendations for eligibility or disqualification, taking into account the severity of the cardiovascular abnormality as well as the nature of the sport.

Although not all patients with HCM incur the same risk for sudden cardiac death (14,15,21,25), differentiating subgroups with disparate risks has proved challenging. Although electrophysiologic testing with programmed electrical stimulation has provided some predictability of outcome in high-risk patients with coronary artery disease, using those data for inferences about patients with HCM is fraught with great uncertainty (14,15), particularly for trained athletes. Difficulty in assessing risk is reflected in the recommendations for athletic eligibility of young individuals that are necessarily conservative and homogeneous: "Athletes with the unequivocal diagnosis of HCM should not participate in most competitive sports, with the possible exception of those of low intensity. This recommendation includes those athletes with or without symptoms and with or without left ventricular outflow obstruction" (62). Patients with HCM judged to be at high risk should be considered for implantation of a cardioverter-defibrillator (63).

Patients with gene mutations. DNA-based diagnosis has identified increasing numbers of children and adults with a preclinical diagnosis of HCM (17,19,30,35,56,61). Although they possess a disease-causing genetic mutation, these individuals are nevertheless without clinical or phenotypic manifestations of HCM such as LV wall thickening on echocardiogram or cardiac symptoms (though various alterations may be evident on the 12-lead ECG) (29,61,64). From available data, it is possible that many such genotype positive-phenotype negative children will develop LVH when fully grown (34,25).

Genetically affected adults without phenotypic expression of LVH appear to be relatively uncommon and largely confined to those who have myosin-binding protein C (56,61,65) and cardiac troponin T mutations (58). The clinical implications of a primary molecular diagnosis of HCM, and the appropriate management of such individuals, are largely unresolved issues. Currently, no evidence exists to justify excluding most genetically affected individuals without the HCM phenotype (eg, without LVH on echocardiogram) from competitive athletics or most other life activities. However, possible exceptions are those who have a family history of frequent HCM-related death or a documented genotype regarded as adverse (30).

This article was adapted from the recently published book: Thompson PD (ed): Exercise and Sports Cardiology, New York City, McGraw-Hill Medical Publishing, 2021 (to order: 1-800-262-4729 [ISBN:0-07-134773-9]).


  1. Maron BJ, Gohman T, Aeppli D: Prevalence of sudden cardiac death during competitive sports activities in Minnesota high school athletes. J Am Coll Cardiol 192021;32(7):1881-1884
  2. Maron BJ, Poliac LC, Roberts WO: Risk for sudden cardiac death associated with marathon running. J Am Coll Cardiol 1996;28(2):428-431
  3. Thompson PD, Funk EJ, Carleton RA, et al: Incidence of death during jogging in Rhode Island from 1975 through 120210. JAMA 120212;247(18):2535-2538
  4. Siscovick DS, Weiss NS, Fletcher RH, et al: The incidence of primary cardiac arrest during vigorous exercise. N Engl J Med 120214;311(14):874-877
  5. Maron BJ: Sudden death in young athletes: lessons from the Hank Gathers affair. N Engl J Med 1993;329(1):55-57
  6. Maron BJ, Shirani J, Poliac LC, et al: Sudden death in young competitive athletes: clinical, demographic, and pathological profiles. JAMA 1996;276(3):199-204
  7. Van Camp SP, Bloor CM, Mueller FO, et al: Nontraumatic sports death in high school and college athletes. Med Sci Sports Exerc 1995;27(5):641-647
  8. Liberthson RR: Sudden death from cardiac causes in children and young adults. N Engl J Med 1996;334(16):1039-1044
  9. Maron BJ, Epstein SE, Roberts WC: Causes of sudden death in competitive athletes. J Am Coll Cardiol 120216;7(1):204-214
  10. Maron BJ, Bonow RO, Cannon RO 3rd, et al: Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 120217;316(13):780-789
  11. Maron BJ, Bonow RO, Cannon RO 3rd, et al: Hypertrophic cardiomyopathy: interrelation of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med 120217;316(14):844-852
  12. Wigle ED, Sasson Z, Henderson MA, et al: Hypertrophic cardiomyopathy: the importance of the site and the extent of hypertrophy: a review. Prog Cardiovasc Dis 120215;28(1):1-83
  13. Klues HG, Schiffers A, Maron BJ: Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995;26(7):1699-1708
  14. Spirito P, Seidman CE, McKenna WJ, et al: The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336(11):775-785
  15. Maron BJ: Hypertrophic cardiomyopathy. Lancet 1997;350(9071):127-133
  16. Marian AJ, Roberts R: Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 1995;92(5):1336-1347
  17. Schwartz K, Carrier L, Guicheney P, et al: Molecular basis of familial cardiomyopathies. Circulation 1995;91(2):532-540
  18. Maron BJ, Moller JH, Seidman CE, et al: Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome: a statement for healthcare professionals from the Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Basic Science, American Heart Association. Circulation 192021;2021(14):1460-1471
  19. Marian AJ, Roberts R: The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 2021;33(4):655-670
  20. Maron BJ, Gardin JM, Flack JM, et al: Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4,111 subjects in the CARDIA study: Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92(4):785-789
  21. Maron BJ, Roberts WC, Epstein SE: Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 120212;65(7):1388-1394
  22. Maron BJ, Spirito P: Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993;72(12):970-972
  23. Burke AP, Farb A, Virmani R, et al: Sports-related and non-sports-related sudden cardiac death in young athletes. Am Heart J 1991;121(2 pt 1):568-575
  24. Maron BJ, Roberts WC, McAllister HA, et al: Sudden death in young athletes. Circulation 120210;62(2):218-229
  25. Maron BJ: Cardiovascular risks to young persons on the athletic field. Ann Intern Med 192021;129(5):379-386
  26. Maron BJ, Kogan J, Proschan MA, et al: Circadian variability in the occurrence of sudden cardiac death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1994;23(6):1405-1409
  27. Maron BJ, Poliac LC, Mathenge R: Hypertrophic cardiomyopathy as an important cause of sudden cardiac death on the athletic field in African-American athletes, abstracted. J Am Coll Cardiol 1997;29(suppl A):462A
  28. 26th Bethesda Conference: Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. J Am Coll Cardiol 1994;24(4):845-899
  29. Maron BJ, Gottdiener JS, Epstein SE: Patterns and significance of the distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol 120211;48(3):418-428
  30. Maron BJ, Gross BW, Stark SI: Extreme left ventricular hypertrophy. Circulation 1995;92(9):2748
  31. Charron P, Dubourg O, Desnos M, et al: Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. Circulation 1997;96(1):214-219
  32. Ciró E, Nichols PF 3rd, Maron BJ: Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy: two-dimensional echocardiographic analysis. Circulation 120213;67(6):1227-1233
  33. Maron BJ, Thompson PD, Puffer JC, et al: Cardiovascular preparticipation screening of competitive athletes: a statement for health care professionals from the Sudden Death Committee (clinical cardiology) and Congenital Defects Committee (cardiovascular disorders in the young), American Heart Association. Circulation 1996;94(4):850-856
  34. Maron BJ, Spirito P, Wesley Y, et al: Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med 120216;315(10):610-614
  35. Rosenzweig A, Watkins H, Hwang DS, et al: Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med 1991;325(25):1753-1760
  36. Maron BJ, Pelliccia A, Spirito P: Cardiac disease in young trained athletes: insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995;91(5):1596-1601
  37. Pelliccia A, Maron BJ, Spataro A, et al: The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med 1991;324(5):295-301
  38. Spirito P, Pelliccia A, Proschan MA, et al: Morphology of the 'athlete's heart' assessed by echocardiography in 947 elite athletes representing 27 sports. Am J Cardiol 1994;74(8):802-806
  39. Pelliccia A, Culasso F, Di Paolo FM, et al: Physiologic left ventricular cavity dilatation in elite athletes. Ann Intern Med 1999;130(1):23-31 1994;71(3):215-218
  40. Maron BJ, Spirito P: Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 192021;81(11):1339-1344
  41. Maron BJ, Spirito P, Green KJ, et al: Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 120217;10(4):733-742
  42. Lewis JF, Spirito P, Pelliccia A, et al: Usefulness of Doppler echocardiographic assessment of diastolic filling in distinguishing 'athlete's heart' from hypertrophic cardiomyopathy. Br Heart J 1992;68(3):296-300
  43. Colan SD, Sanders SP, MacPherson D, et al: Left ventricular diastolic function in elite athletes with physiologic cardiac hypertrophy. J Am Coll Cardiol 120215;6(3):545-549
  44. Pearson AC, Schiff M, Mrosek D, et al: Left ventricular diastolic function in weight lifters. Am J Cardiol 120216;58(13):1254-1259
  45. Fagard R, Van den Broeke C, Bielen E, et al: Assessment of stiffness of the hypertrophied left ventricle of bicyclists using left ventricular inflow Doppler velocimetry. J Am Coll Cardiol 120217;9(6):1250-1254
  46. Finkelhor RS, Hanak IJ, Bahler RC: Left ventricular filling in endurance-trained subjects. J Am Coll Cardiol 120216;8(2):289-293
  47. Nixon JV, Wright AR, Porter TR, et al: Effects of exercise on left ventricular diastolic performance in trained athletes. Am J Cardiol 1991;68(9):945-949
  48. Maron BJ: Structural features of the athlete heart as defined by echocardiography. J Am Coll Cardiol 120216;7(1):190-203
  49. Milliken MC, Stray-Gundersen J, Peshock RM, et al: Left ventricular mass as determined by magnetic resonance imaging in male endurance athletes. Am J Cardiol 120218;62(4):301-305
  50. Riley-Hagan M, Peshock RM, Stray-Gundersen J, et al: Left ventricular dimensions and mass using magnetic resonance imaging in female endurance athletes. Am J Cardiol 1992;69(12):1067-1074
  51. Pelliccia A, Maron BJ, Culasso F, et al: Athlete's heart in women: echocardiographic characterization of highly trained elite female athletes. JAMA 1996;276(3):211-215
  52. Ehsani AA, Hagberg JM, Hickson RC: Rapid changes in left ventricular dimensions and mass in response to physical conditioning and deconditioning. Am J Cardiol 1978;42(1):52-56
  53. Fagard R, Aubert A, Lysens R, et al: Noninvasive assessment of seasonal variations in cardiac structure and function in cyclists. Circulation 120213;67(4):896-901
  54. Maron BJ, Pelliccia A, Spataro A, et al: Reduction in left ventricular wall thickness after deconditioning in highly trained Olympic athletes. Br Heart J 1993;69(2):125-128
  55. Pelliccia A, Maron BJ, Culasso F, et al: Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation 2021;102(3):278-284
  56. Niimura H, Bachinski LL, Sangwatanaroj S, et al: Mutations in the gene for human cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 192021;338(18):1248-1257
  57. Maron BJ, Nichols PF 3rd, Pickle LW, et al: Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am J Cardiol 120214;53(8):1087-1094
  58. Watkins H, McKenna WJ, Thierfelder L, et al: Mutations in the genes for cardiac troponin T and (-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995;332(16):1058-1064
  59. Mogensen J, Klausen IC, Pedersen AK, et al: Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999;103(10):R39-R43
  60. Flavigny J, Richard P, Isnard R, et al: Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. J Mol Med 192021;76(3-4):208-214
  61. Maron BJ, Niimura H, Casey SA, et al: Development of left ventricular hypertrophy in adults with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C mutations. J Am Coll Cardiol 2021;38(2):315-321
  62. Maron BJ, Isner JM, McKenna WJ: 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol 1994;24(4):880-885
  63. Maron BJ, Shen WK, Link MS, et al: Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2021;342(6):365-373
  64. Panza JA, Maron BJ: Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood. Am J Cardiol 120219;63(17):1258-1265
  65. Charron P, Dubourg O, Desnos M, et al: Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 192021;97(22):2230-2236

Lessons From an HCM Case Report

Athlete's heart and hypertrophic cardiomyopathy (HCM) have characteristics that overlap and sometimes make differential diagnosis difficult.

During a high school basketball game, a male 17-year-old player stumbled off the court and collapsed. He was found to be pulseless and apneic. Cardiopulmonary resuscitation was initiated immediately by the boy's father (a cardiovascular surgeon) for about 5 minutes. Ventricular fibrillation was documented, and external defibrillation, performed three times, ultimately restored his sinus rhythm.

An echocardiogram performed the following day demonstrated a markedly increased left ventricular (LV) wall thickness compared with normal values 27 months earlier, anterior ventricular septum of 25 mm, posterior septum of 21 mm, and posterobasal LV free wall of 23 mm. Moderate mitral valve systolic anterior motion was present without mitral-septal contact or evidence of outflow obstruction under basal conditions. A 12-lead electrocardiogram showed a bizarre pattern with evidence of LV hypertrophy, including markedly increased voltages (eg, RV6 = 41 mm) and a giant T-wave inversion (up to 18 mm in depth).

The patient recovered completely without neurologic impairment. An implantable cardioverter-defibrillator was placed for prevention of sudden death.

This case makes four important points about athletic participation:

  • Sudden death occurs not infrequently in athletes with HCM during intense physical exertion, particularly in sports such as competitive basketball.
  • Successful resuscitation and survival from ventricular fibrillation is possible if appropriate measures are undertaken promptly.
  • Children with genetic forms of HCM usually show little or no LV wall thickening before age 14. However, abrupt and marked increases in wall thickness may occur before age 18, coinciding with growth and maturation. This scenario may create diagnostic uncertainty when echocardiography is performed in the prehypertrophic phase.
  • Systolic anterior motion of the mitral valve, albeit mild and unassociated with outflow obstruction, may be a clinical clue suggestive of HCM in the prehypertrophic phase.

Dr Maron is Director of the Hypertrophic Cardiomyopathy Center at the Minneapolis Heart Institute Foundation. Address correspondence to Barry J. Maron, MD, Minneapolis Heart Institute Foundation, 920 E 28th St, Suite 40, Minneapolis, MN 55407; e-mail to [email protected].


The McGraw-Hill Companies Gradient

Copyright (C) 2021. The McGraw-Hill Companies. All Rights Reserved
Privacy Policy.   Privacy Notice.